U.S. flag

An official website of the United States government

GRCh37/hg19 16p13.3(chr16:2635096-2830625)x1 AND not provided

Germline classification:
Uncertain significance (1 submission)
Last evaluated:
Jan 18, 2021
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV001795864.4

Allele description [Variation Report for GRCh37/hg19 16p13.3(chr16:2635096-2830625)x1]

GRCh37/hg19 16p13.3(chr16:2635096-2830625)x1

Genes:
PDPK1:3-phosphoinositide dependent protein kinase 1 [Gene - OMIM - HGNC]
ELOB:elongin B [Gene - OMIM - HGNC]
KCTD5:potassium channel tetramerization domain containing 5 [Gene - OMIM - HGNC]
PRSS27:serine protease 27 [Gene - OMIM - HGNC]
SRRM2:serine/arginine repetitive matrix 2 [Gene - OMIM - HGNC]
Variant type:
copy number loss
Cytogenetic location:
16p13.3
Genomic location:
Chr16: 2635096 - 2830625 (on Assembly GRCh37)
Preferred name:
GRCh37/hg19 16p13.3(chr16:2635096-2830625)x1
HGVS:

    Condition(s)

    Synonyms:
    none provided
    Identifiers:
    MedGen: CN517202

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...

    Assertion and evidence details

    Submission AccessionSubmitterReview Status
    (Assertion method)
    Clinical Significance
    (Last evaluated)
    OriginMethodCitations
    SCV002037188Illumina Laboratory Services, Illumina
    criteria provided, single submitter

    (ICSL CNVClassificationCriteria Aug2020)
    Uncertain significance
    (Jan 18, 2021)
    unknownclinical testing

    PubMed (2)
    [See all records that cite these PMIDs]

    Citation Link

    Summary from all submissions

    EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
    not providedunknownunknownnot providednot providednot providednot providednot providedclinical testing

    Citations

    PubMed

    A new microdeletion syndrome involving TBC1D24, ATP6V0C, and PDPK1 causes epilepsy, microcephaly, and developmental delay.

    Mucha BE, Banka S, Ajeawung NF, Molidperee S, Chen GG, Koenig MK, Adejumo RB, Till M, Harbord M, Perrier R, Lemyre E, Boucher RM, Skotko BG, Waxler JL, Thomas MA, Hodge JC, Gecz J, Nicholl J, McGregor L, Linden T, Sisodiya SM, Sanlaville D, et al.

    Genet Med. 2019 May;21(5):1058-1064. doi: 10.1038/s41436-018-0290-3. Epub 2018 Sep 24. Erratum in: Genet Med. 2019 Sep;21(9):2159-2160. doi: 10.1038/s41436-018-0413-x.

    PubMed [citation]
    PMID:
    30245510

    Refinement of 16p13.3 microdeletion syndrome from a case presentation of a girl with epilepsy and intellectual disability.

    Kuroda Y, Kimura Y, Uehara T, Kosaki K, Kurosawa K.

    Congenit Anom (Kyoto). 2020 Mar;60(2):75-77. doi: 10.1111/cga.12347. Epub 2019 Jul 4. No abstract available.

    PubMed [citation]
    PMID:
    31231897

    Details of each submission

    From Illumina Laboratory Services, Illumina, SCV002037188.1

    #EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
    1not providednot providednot providednot providedclinical testing PubMed (2)

    Description

    This CNV is a 196 kb deletion of 16p13.3, on chromosome 16, (seq[GRCh37]del(16)(p13.3); chr16:g.2635096_2830625del) which has been identified in a de novo state. This CNV constitutes a loss encompassing the following protein coding genes: ELOB, KCTD5, PDPK1, PRSS21, PRSS27, PRSS33, PRSS41, SRRM2, ZG16B, and partially overlaps the 16p13.3 microdeletion syndrome region. Mucha et al. (2019) reported eight individuals with overlapping deletions ranging from 205 kb to 504 kb in 16p13.3, and describe a minimal overlapping region encompassing three genes, TBC1D24, ATP6V0C, and PDPK1. At least six microdeletions were confirmed de novo. Common features of the syndrome included developmental delay, intellectual disability, and epilepsy. Additional features in these individuals included microcephaly, mildly dysmorphic features, hearing loss, strabismus, feeding difficulties, failure to thrive, short stature, behavioral problems including autism spectrum disorder, ADHD, and mania/bipolar episodes, and rarely an abnormal brain MRI. Additionally, in one individual with severe intellectual disability, epileptic seizures, skeletal abnormalities, and dysmorphic features, a de novo microdeletion at 16p13.3 involving TBC1D24 and ATP6V0C was reported (Kuroda et al. 2019). The CNV found in the proband overlaps at least six of the deletions reported in Mucha et al. (2019), but does not overlap the region of minimal overlap. This CNV has not been reported in controls. Based on the limited evidence currently available, this CNV is classified as a variant of uncertain significance.

    #SampleMethodObservation
    OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
    1unknownunknownnot providednot providednot providednot providednot providednot providednot provided

    Last Updated: Apr 9, 2023